Rebamipide for the Improvement of Gastric Atrophy and Intestinal Metaplasia: A Prospective, Randomized, Pilot Study

Abstract

The presence of atrophic gastritis (AG) and intestinal metaplasia (IM) is associated with an increased risk of gastric cancer (GC). Thus, the development of new strategies to improve AG/IM is essential for reducing the incidence of GC. We aimed to evaluate the efficacy of rebamipide for improving AG/IM. This was a prospective, randomized, pilot study from a single tertiary referral center. Fifty-three (rebamipide, n\u2009=\u200934 vs. placebo, n\u2009=\u200919) patients, who underwent endoscopic resection for gastric dysplasia or early GC, were analyzed. We obtained tissue samples from the antrum and corpus of the stomach, at the time of screening and 1-year later. The histologic grading of inflammation was performed by histopathologists The AG grade in the antrum improved significantly after rebamipide treatment (pre-administration, 1.870\u2009±\u20090.932 vs. post-administration, 1.430\u2009±\u20090.986; P\u2009=\u20090.013). Additionally, the severity of IM in the antrum was significantly improved (pre-administration, 1.750\u2009±\u20090.963 vs. post-administration, 1.370\u2009±\u20091.032; P\u2009=\u20090.038). The rebamipide subgroup analysis revealed that patients with no Helicobacter pylori (HP) infection showed significant improvements in AG in the antrum (pre-administration, 1.880\u2009±\u20091.040 vs. post-administration, 1.250\u2009±\u20090.894; P\u2009=\u20090.028) and IM in antrum (pre-administration, 1.840\u2009±\u20091.012 vs. post-administration, 1.180\u2009±\u20090.912; P\u2009=\u20090.020). This study demonstrated that the administration of rebamipide improves AG and IM in the antrum, especially in patients with HP non-infection (KCT0001915).